FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

7 letters match. Newest first.

  1. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  2. Signature Formulations, LLC

    FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

    High risk
  3. Colgate-Palmolive/Tom's of Maine, Inc.

    FDA cited Tom's of Maine for CGMP failures after finding objectionable microbes in water and toothpaste and inadequate complaint handling.

    High risk
  4. AmLion Toothpaste Mfg. Sdn. Bhd.

    FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.

    High risk
  5. Zhao Qing Longda Biotechnology Co. Ltd.

    FDA says Zhao Qing Longda Biotechnology refused records access for OTC drugs, including children’s toothpaste, and placed its drugs on import alert.

    High risk
  6. Sangleaf Pharm., Co. Ltd.

    Sangleaf Pharm failed to give FDA requested records for OTC drugs, including children's toothpaste, at risk of DEG/EG contamination.

    High risk
  7. Suhan Aerosol

    Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.

    High risk